This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.

Kaye Scholer Advises Pfizer in Acquisition of Bamboo Therapeutics

August 1, 2016

Kaye Scholer advised longtime client Pfizer Inc. in its acquisition of Bamboo Therapeutics, Inc., a privately held biotechnology company. Kaye Scholer previously represented Pfizer in its acquisition of approximately 22 percent of Bamboo’s fully diluted equity for a payment of approximately $43 million during the first quarter of 2016. Under the terms of the current transaction, Pfizer acquired all of the remaining equity of Bamboo for an upfront cash payment of $150 million, with up to $495 million of contingent milestone payments.

The Kaye Scholer Corporate team was led by Corporate partner Lowell I. Dashefsky and associates Eric M. Levine and Danielle N. Rosato, with support from Tax & Private Clients partners Laurie Abramowitz and Jeffrey L. London, associates Brian Witkoswki and Gus Weinkam, Litigation counsel Paula Ramer and Corporate associate Connie Ericson.

» Read Pfizer's press release for more background on the transaction.

Also of Interest